BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 23226683)

  • 1. Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex.
    Przysiecki C; Lucas B; Mitchell R; Carapau D; Wen Z; Xu H; Wang XM; Nahas D; Wu C; Hepler R; Ottinger E; Ter Meulen J; Kaslow D; Shiver J; Nardin E
    Front Cell Infect Microbiol; 2012; 2():146. PubMed ID: 23226683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses.
    Powell TJ; Tang J; Derome ME; Mitchell RA; Jacobs A; Deng Y; Palath N; Cardenas E; Boyd JG; Nardin E
    Vaccine; 2013 Apr; 31(15):1898-904. PubMed ID: 23481177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine.
    McCoy ME; Golden HE; Doll TA; Yang Y; Kaba SA; Zou X; Gerbasi VR; Burkhard P; Lanar DE
    Malar J; 2013 Apr; 12():136. PubMed ID: 23607541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin.
    Carapau D; Mitchell R; Nacer A; Shaw A; Othoro C; Frevert U; Nardin E
    Infect Immun; 2013 Dec; 81(12):4350-62. PubMed ID: 24042110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint.
    Porter MD; Nicki J; Pool CD; DeBot M; Illam RM; Brando C; Bozick B; De La Vega P; Angra D; Spaccapelo R; Crisanti A; Murphy JR; Bennett JW; Schwenk RJ; Ockenhouse CF; Dutta S
    Clin Vaccine Immunol; 2013 Jun; 20(6):803-10. PubMed ID: 23536694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts.
    Birkett A; Lyons K; Schmidt A; Boyd D; Oliveira GA; Siddique A; Nussenzweig R; Calvo-Calle JM; Nardin E
    Infect Immun; 2002 Dec; 70(12):6860-70. PubMed ID: 12438363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.
    Khan F; Porter M; Schwenk R; DeBot M; Saudan P; Dutta S
    PLoS One; 2015; 10(11):e0142035. PubMed ID: 26571021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenicity and immunogenicity of a novel chimeric peptide antigen based on the P. vivax circumsporozoite protein.
    Céspedes N; Arévalo-Herrera M; Felger I; Reed S; Kajava AV; Corradin G; Herrera S
    Vaccine; 2013 Oct; 31(42):4923-30. PubMed ID: 23954378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
    Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
    Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod.
    Othoro C; Johnston D; Lee R; Soverow J; Bystryn JC; Nardin E
    Infect Immun; 2009 Feb; 77(2):739-48. PubMed ID: 19047411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein.
    Iyori M; Nakaya H; Inagaki K; Pichyangkul S; Yamamoto DS; Kawasaki M; Kwak K; Mizukoshi M; Goto Y; Matsuoka H; Matsumoto M; Yoshida S
    PLoS One; 2013; 8(8):e70819. PubMed ID: 23951015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge.
    Calvo-Calle JM; Oliveira GA; Watta CO; Soverow J; Parra-Lopez C; Nardin EH
    Infect Immun; 2006 Dec; 74(12):6929-39. PubMed ID: 17030584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes.
    Phares TW; May AD; Genito CJ; Hoyt NA; Khan FA; Porter MD; DeBot M; Waters NC; Saudan P; Dutta S
    Malar J; 2017 Mar; 16(1):115. PubMed ID: 28288639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on B- and T-cell epitopes of the Plasmodium falciparum CS protein: possible vaccine application.
    de Oliveira GA; Clavijo P; Nussenzweig RS; Nardin EH
    Vaccine; 1994 Aug; 12(11):1012-7. PubMed ID: 7526570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An unstable Th epitope of P. falciparum fosters central memory T cells and anti-CS antibody responses.
    Parra-López CA; Bernal-Estévez D; Yin L; Vargas LE; Pulido-Calixto C; Salazar LM; Calvo-Calle JM; Stern LJ
    PLoS One; 2014; 9(7):e100639. PubMed ID: 24983460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice.
    Moreno CA; Rodriguez R; Oliveira GA; Ferreira V; Nussenzweig RS; Moya Castro ZR; Calvo-Calle JM; Nardin E
    Vaccine; 1999 Aug; 18(1-2):89-99. PubMed ID: 10501239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.
    Patra KP; Li F; Carter D; Gregory JA; Baga S; Reed SG; Mayfield SP; Vinetz JM
    Infect Immun; 2015 May; 83(5):1799-808. PubMed ID: 25690099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein.
    Persson C; Oliveira GA; Sultan AA; Bhanot P; Nussenzweig V; Nardin E
    J Immunol; 2002 Dec; 169(12):6681-5. PubMed ID: 12471098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
    PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.